Henri B. Meier

Tensys Medical, Inc. develops blood pressure monitoring systems. The firm provides patient safety by designing, and manufacturing continuous, non-invasive hemodynamic monitoring systems. The company was founded in 1995 and is headquartered in San Diego, CA.

Ellipse Technologies, Inc. develops and commercializes implants for spinal and orthopedic applications. It designs, develop and commercialize non-invasively adjustable, remote controlled implants for a broad spectrum of spinal and orthopedic applications. The company was founded by Samuel M. Shaolian and Shawn Moaddeb on June 30, 2005 and is headquartered in Aliso Viejo, CA.

Cardialen, Inc. develops medical devices. It offers pain-free cardio version therapy for atrial fibrillation (AF) using low-energy implantable atrial cardioverters. The firm develops and commercializes these as an independent specialist, to address major needs in atrial fibrillation management, achieve improved outcomes and reduce the risk of stroke, heart failure and high healthcare costs associated with atrial fibrillation. The company's products comprise implantable low-energy pain-free atrial cardioverters and cardiac leads and defibrillator equipment. Its products are used for the treatment of atrial and ventricular arrhythmias. Cardialen was founded in 2008 by D. Graeme Thomas, Randy H. Weiss and Igor R. Efimov and is headquartered in St. Louis, MO.

Vascular Dynamics, Inc. provides blood pressure modulation devices. It develops and commercializes a passive, catheter-delivered implant for the treatment of hypertension. The company was founded in 2008 and is headquartered in Mountain View, CA.

Bank Julius Bär & Co. AG (BJB) is the private banking subsidiary of Julius Bär Gruppe AG (SWX: BAER) in Switzerland. Headquartered in Zurich, BJB was founded in 1890 and provides personal wealth management advice to private clients and family offices.

Credit Suisse AG is an investment management firm headquartered in Zurich, Switzerland. The firm was founded in 1856 and was acquired by UBS Group AG (SWX: UBSG) from Credit Suisse Group AG in 2023. Credit Suisse manages global and regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals worldwide. They also offer private banking and wealth management, investment banking, and corporate and business support services.

Zellweger Luwa AG is a Swiss industrial company that, together with its subsidiaries, operates in the fields of gas detection and air engineering. It has two business divisions. The Zellweger Analytics division specializes in the supply of gas detection systems. Its product range, which includes gas detection systems for toxic gases, gas detection systems for explosive gases, portable gas detection systems and CO (carbon monoxide) detectors, is sold under the MDA Scientific, Sieger and Neotronics brand names to the oil and gas, semiconductor, petrochemicals, utilities and other industries. These systems are designed to protect people and the environment against harmful gases. The Luwa division focuses on the development of air engineering systems for the textile, pharmaceutical, electronics and other industries. Its product portfolio consists of textile air engineering systems, cleanroom technology and general-purpose air engineering systems. The Company's products are sold worldwide.

Thommen Medical AG develops and manufactures dental implant systems. It offers include implants, prosthetics, digital solutions, and case planning. The company Grenchen, Switzerland.

Part of Boston Scientific Corp., Schneider (Europe) GmbH is a Swiss company that makes stents used to prop open arteries and other devices for angioplasty. The company is based in Bulach, Switzerland. Schneider (Europe was acquired by Boston Scientific Corp. from Pfizer Inc. on September 10, 1998 for $2,100 million.

ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland.

Zürcher Kantonalbank (Broker) (ZKB-Broker) is the brokerage business unit of Zürcher Kantonalbank, a state-owned full-service bank founded in 1870, which is headquartered in Zurich, Switzerland. They conduct all investment activities in-house including financial advisory services, research, trading, and asset management. ZKB-Broker is an active trader in securities, foreign currencies, banknotes, precious metals, commodity contracts and financial derivatives on their own account and on behalf of third-party customers. The bank provides underwriting services in domestic debt and equity markets, sales and trading of listed domestic warrants and structured derivatives, and Swiss Franc foreign exchange trading. The firm offers round-the-clock market-making in credit default swaps from Swiss issuers. Their research covers a broad international investment universe and maintains a successful equity, bonds and sustainability research capability, together with independent investment fund research.

Curetis GmbH operates as a molecular diagnostics company which focuses on the development and commercialization of products for diagnosing severe infectious diseases. The firm offers diagnostic solutions for hospitals and large-scale laboratories. Its products include Unyvero L4 Lysator, Unyvero C8 Cockpit, Unyvero A50 Analyzer, and Unyvero Application Cartridges. The company was founded by Andreas Boos, Johannes Bacher, Gerd Lüdke, and Anne Thews in August 2007 and is headquartered in Holzgerlingen, Germany.

Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland.

Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA.

Gebrüder Meier AG is a company based in Regensdorf, Switzerland. The Swiss company provides repair services for electric motors and frequency converters. Part of ERNE AG Bauunternehmung, Gebrüder Meier AG was founded in 1998. Daniel G. Zeidler has been the CEO of the company since 2022.

Part of Enovis Corp., Mathys AG Bettlach is a company that focuses on developing innovative solutions in collaboration with clinical partners to enable mobility preservation. Mathys AG Bettlach is based in Bettlach, Switzerland. Mathys AG Bettlach was acquired by DJO LLC from Mathys AG on July 28, 2021 for $299.28 million. The Swiss company values international exchange with surgeons to address previously unresolved clinical problems. The company was founded in 1946 by Robert Mathys, and Benjamin Reinmann has been the CEO of the company since 2017.

Humedics GmbH operates as a research-based medtech company. It focuses on rapid and precise lover function measurement using LiMax, a breath analysis technology. The company was founded by Martin Stockman, Erwin de Bujizer, and Karsten Heyne in 2009 and is headquartered in Berlin, Germany.

APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria.

AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany.

Part of HBM Partners AG, HBM Healthcare Investments (Cayman) Ltd. provides healthcare services. The company is based in George Town, Cayman Islands. Andreas Wicki has been the CEO of the company since 2001.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

Reha Technology AG designs, manufactures and distributes robotic-assisted systems for neuro-rehabilitation. Its products include G-EO system, nexstep, first mover and armotion. The company was founded in 2011 and is headquartered in Olten, Switzerland.

HBM Partners AG (Investment Management) (HBM-IM) is the asset management division of HBM Partners AG. The firm is headquartered in Zug and was founded in 2001. HBM-IM provides investment advisory services to private companies. They manage the fund HBM Healthcare Investments.

Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany.

Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada.

Swixx Biopharma SA provides marketing and sales, regulatory, medical affairs, cold chain, logistic services to pharmaceutical companies. Its services also include receivables, collection, FX coverage, risk management, compliance, and reimbursement and market access. The company was founded by Petr Nemec and Robert Stuart Swanson in 2013 and is headquartered in Baar, Switzerland.

Mahzi Therapeutics is a private biotechnology company that focuses on genetic therapies for rare genetic neurodevelopmental disorders. The company was founded by Yael Weiss and is based in San Mateo, CA. The company unites patient and family groups, academic researchers, diagnostic companies, other industry members, and its internal team of experts to develop therapies for patients with these serious diseases. Mahzi's team is experienced in all aspects of biopharmaceutical research, development, and manufacturing and is driven to make a difference in the lives of patients with rare genetic diseases. Yael Weiss has been the CEO since incorporation.

Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland.

AdrenoMed AG develops a drug to decrease mortality in severe sepsis. The company was founded by Bernd Wegener, Gerald Heinz Möller and Andreas Bergmann in 2009 and is headquartered in Berlin, Germany.

ValCare Medical, Inc. engages in the designing, developing and commercializing devices and accessories for minimally invasive treatment of heart valve diseases. The firm develops a unique transcatheter device, which will provide the capability to implant the mitral annuloplasty device interventionally without surgery. The company was founded by Samuel M. Shaolian in 2012 and is headquartered in Herzlyia Pituach, Israel.